What is Zacks Research’s Forecast for SRPT Q1 Earnings?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Research analysts at Zacks Research cut their Q1 2025 earnings per share (EPS) estimates for shares of Sarepta Therapeutics in a research note issued on Monday, January 6th. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will earn $1.90 per share for the quarter, down from their prior forecast of $1.98. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.16 per share. Zacks Research also issued estimates for Sarepta Therapeutics’ Q2 2025 earnings at $2.63 EPS, Q3 2025 earnings at $2.60 EPS, Q4 2025 earnings at $2.83 EPS, FY2025 earnings at $9.95 EPS, Q1 2026 earnings at $3.04 EPS, Q2 2026 earnings at $3.56 EPS, Q3 2026 earnings at $3.53 EPS, Q4 2026 earnings at $3.53 EPS and FY2026 earnings at $13.66 EPS.

SRPT has been the subject of several other reports. Jefferies Financial Group assumed coverage on shares of Sarepta Therapeutics in a report on Monday, October 21st. They issued a “buy” rating and a $165.00 price objective for the company. Needham & Company LLC lowered their target price on shares of Sarepta Therapeutics from $205.00 to $202.00 and set a “buy” rating on the stock in a research note on Wednesday, November 27th. Piper Sandler reduced their price target on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research report on Wednesday, November 27th. Royal Bank of Canada reiterated an “outperform” rating and issued a $182.00 price objective on shares of Sarepta Therapeutics in a research report on Monday, October 21st. Finally, Evercore ISI reduced their target price on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $178.71.

Sarepta Therapeutics Trading Up 1.4 %

Shares of Sarepta Therapeutics stock opened at $126.27 on Thursday. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The stock has a market capitalization of $12.06 billion, a P/E ratio of 101.02 and a beta of 0.77. Sarepta Therapeutics has a 52-week low of $102.15 and a 52-week high of $173.25. The stock’s 50-day simple moving average is $122.11 and its 200 day simple moving average is $131.33.

Insider Buying and Selling

In other news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the sale, the director now owns 22,840 shares of the company’s stock, valued at approximately $2,851,345.60. This represents a 31.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the completion of the transaction, the director now directly owns 5,880 shares in the company, valued at approximately $738,234. The trade was a 21.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Sunbelt Securities Inc. lifted its stake in Sarepta Therapeutics by 446.2% in the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 232 shares during the period. Huntington National Bank raised its holdings in Sarepta Therapeutics by 150.9% in the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 175 shares in the last quarter. Nkcfo LLC purchased a new stake in shares of Sarepta Therapeutics in the 2nd quarter worth about $43,000. UMB Bank n.a. boosted its stake in shares of Sarepta Therapeutics by 105.9% during the 3rd quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 197 shares in the last quarter. Finally, Values First Advisors Inc. purchased a new position in shares of Sarepta Therapeutics during the third quarter valued at about $59,000. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.